AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9341056 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic CPAP at estimated reference pressure (group 3)
Number of subjects: 36
Study 7924776 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (720 pM.m-2.min-1) during hypoglycemia (target plasma glucose, 2.8 mM)
Number of subjects: 24
Study 7924776 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased insulin infusion rate (1,440 pM.m-2.min-1)
Number of subjects: 24
Study 7924776 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged hypoglycemia (1 h)
Number of subjects: 24
Study 2729537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine hydrochloride 1% (Novesin)
Number of subjects: 70
Study 2729537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (Xylocaine)
Number of subjects: 70
Study 2729537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine hydrochloride 1% (Novesin) without bronchoscopy (group 3)
Number of subjects: 70
Study 2729537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (Xylocaine) without bronchoscopy (group 3)
Number of subjects: 70
Study 2729537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal administration of 10 ml 0.9% NaCl (group 4)
Number of subjects: 70
Study 921876 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 57
Study 921876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 57
Study 31895273 — intervention group
Group type: EXPERIMENTAL
Intervention: Senofilcon A photochromic contact lens
Number of subjects: 24
Study 30938035 — intervention group
Group type: EXPERIMENTAL
Intervention: FBG target of 3.9 < FBG ≤5.6 mmol/L (Group 1)
Number of subjects: 947
Study 30938035 — intervention group
Group type: EXPERIMENTAL
Intervention: FBG target of 3.9 < FBG ≤6.1 mmol/L (Group 2)
Number of subjects: 947
Study 30938035 — intervention group
Group type: EXPERIMENTAL
Intervention: FBG target of 3.9 < FBG ≤7.0 mmol/L (Group 3)
Number of subjects: 947
Study 29145948 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxysmal AF
Number of subjects: 15415
Study 29145948 — intervention group
Group type: EXPERIMENTAL
Intervention: New onset AF
Number of subjects: 15415
Study 29145948 — intervention group
Group type: COMPARATOR
Intervention: Persistent or permanent AF
Number of subjects: 15415
Study 26524106 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous haemopoietic stem cell transplantation (HSCT)
Number of subjects: 2000
Study 23126492 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical box preparation (size #60)
Number of subjects: 24
Study 23126492 — intervention group
Group type: COMPARATOR
Intervention: Apical cone preparation (apical size #25)
Number of subjects: 24
Study 23126492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (apical box and apical cone)
Number of subjects: 24
Study 21876360 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid (PUFA) supplementation
Number of subjects: 16
Study 21876360 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid plus fish gelatin (PUFA+FG) supplementation
Number of subjects: 16
Study 21876360 — intervention group
Group type: COMPARATOR
Intervention: n‐3 PUFA and n‐3 PUFA+FG supplementations
Number of subjects: 16
Study 19561263 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoembolization (IE) with granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at high-dose (>or=1500 microg)
Number of subjects: 53
Study 19561263 — intervention group
Group type: COMPARATOR
Intervention: Chemoembolization (CE)
Number of subjects: 53
Study 19561263 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of hepatic metastases after embolization
Number of subjects: 53
Study 19561263 — intervention group
Group type: COMPARATOR
Intervention: No regression of hepatic metastases after embolization
Number of subjects: 53
Study 16646655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopy training model (TMU)
Number of subjects: 16
Study 16646655 — intervention group
Group type: EXPERIMENTAL
Intervention: Simbionix UROMentor virtual‐reality simulator (VRS)
Number of subjects: 16
Study 14754702 — intervention group
Group type: EXPERIMENTAL
Intervention: ZYC101a (100 or 200 microg)
Number of subjects: 161
Study 14754702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 14754702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ZYC101a groups
Number of subjects: 161
Study 11571979 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum (PP group)
Number of subjects: 34
Study 11571979 — intervention group
Group type: COMPARATOR
Intervention: Abdominal wall retraction (AWR group)
Number of subjects: 34
Study 11571979 — intervention group
Group type: COMPARATOR
Intervention: Comparison between PP and AWR groups
Number of subjects: 34
Study 8779400 — intervention group
Group type: COMPARATOR
Intervention: Randomized studies in emergency medicine
Number of subjects: 0
Study 8779400 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred consent principle
Number of subjects: 0
Study 8779400 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective randomized study
Number of subjects: 0
Study 8779400 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility of a study
Number of subjects: 0
Study 8779400 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent observer involvement
Number of subjects: 0
Study 2008953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg
Number of subjects: 62
Study 2008953 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.125%
Number of subjects: 62
Study 2008953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IT morphine and epidural bupivacaine
Number of subjects: 62
Study 7035953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (2 mg per kilogram of body weight per day) with prednisone in tapering doses
Number of subjects: 50
Study 7035953 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (0.15 mg per kilogram per day) with prednisone in tapering doses
Number of subjects: 50
Study 7035953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic drugs (Cyclophosphamide or Chlorambucil)
Number of subjects: 50
Study 30839267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention from Well Elderly II RCT, specific details not available
Number of subjects: 0
Study 30839267 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting a small subgroup of participants
Number of subjects: 0
Study 30839267 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of clinical meaningfulness methods
Number of subjects: 0
Study 28380086 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% CPC, 0.28% Zn and 0.05% F (CPC+Zn+F)
Number of subjects: 60
Study 28380086 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate (CHX)
Number of subjects: 60
Study 28380086 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 60
Study 28380086 — intervention group
Group type: COMPARATOR
Intervention: No rinsing
Number of subjects: 60
Study 26099868 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 2% lidocaine
Number of subjects: 60
Study 26099868 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 25-mg tramadol
Number of subjects: 60
Study 26099868 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 2% lidocaine + 25-mg tramadol
Number of subjects: 60
Study 23362808 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-sprinting training (20 min of intermittent sprinting on a cycle ergometer: 8 s sprint, 12 s recovery) for 12 weeks
Number of subjects: 16
Study 23362808 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline heart rate variability high-frequency power
Number of subjects: 16
Study 23362808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 16
Study 19930728 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric feeding
Number of subjects: 104
Study 19930728 — intervention group
Group type: COMPARATOR
Intervention: Post-pyloric feeding
Number of subjects: 104
Study 17318453 — intervention group
Group type: EXPERIMENTAL
Intervention: Written method of family history assessment
Number of subjects: 104
Study 17318453 — intervention group
Group type: COMPARATOR
Intervention: Interview method of family history assessment
Number of subjects: 104
Study 17318453 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors (information-seeking, worry, perceived risk, health literacy)
Number of subjects: 104
Study 15330492 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa extract (10 g dry calyx in 0.51 L water, 9.6 mg anthocyanins)
Number of subjects: 90
Study 15330492 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg twice a day)
Number of subjects: 90
Study 11583480 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib sodium (1 mg, 2 mg, 5 mg, 10 mg, 20 mg, or 40 mg)
Number of subjects: 56
Study 11583480 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study 9720702 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of prednisolone in a monthly oral pulse (Group A, aged 12 to 18 years)
Number of subjects: 16
Study 9720702 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate as soluble tablets or syrup equivalent to prednisolone 5 mg/kg body weight every month (Group B, aged 3 to 11 years)
Number of subjects: 16
Study 9720702 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 16
Study 9720702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed doses of corticosteroid (both groups)
Number of subjects: 16
Study 8131343 — intervention group
Group type: EXPERIMENTAL
Intervention: alfacalcidol 0.25 microgram twice daily with calcium 500 mg twice daily
Number of subjects: 66
Study 8131343 — intervention group
Group type: COMPARATOR
Intervention: placebo twice daily with calcium 500 mg twice daily
Number of subjects: 66
Study 2093414 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine-raubasine
Number of subjects: 204
Study 2093414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 642493 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of albumin during operation followed by 150 g/day for 5 days
Number of subjects: 52
Study 642493 — intervention group
Group type: COMPARATOR
Intervention: No albumin
Number of subjects: 52
Study 30910321 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 782
Study 30910321 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 782
Study 28382336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented Maillard-reactive whey protein (F-MRP) 6 g/day for 8 weeks
Number of subjects: 80
Study 28382336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) 6 g/day for 8 weeks
Number of subjects: 80
Study 28382336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented Maillard-reactive whey protein (F-MRP)
Number of subjects: 80
Study 25880486 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims-based algorithm for identifying eligible participants
Number of subjects: 3591
Study 25880486 — intervention group
Group type: COMPARATOR
Intervention: Medical record review (gold standard)
Number of subjects: 3591
Study 23696598 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 67
Study 23696598 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 67
Study 23696598 — intervention group
Group type: COMPARATOR
Intervention: Angiographic assessment
Number of subjects: 67
Study 21211643 — intervention group
Group type: EXPERIMENTAL
Intervention: Timothy grass allergy immunotherapy tablet (AIT) treatment
Number of subjects: 439
Study 21211643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 20068276 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (MCFG) 2 mg/kg/day (max 100 mg/day)
Number of subjects: 0
Study 20068276 — intervention group
Group type: COMPARATOR
Intervention: Fosfluconazole (FF) 10 mg/kg/day (max 400 mg/day)
Number of subjects: 0
Study 17046262 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes open with light touch contact
Number of subjects: 10
Study 17046262 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes closed with light touch contact
Number of subjects: 10
Study 17046262 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes open without light touch contact
Number of subjects: 10
Study 17046262 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes closed without light touch contact
Number of subjects: 10
Study 17046262 — intervention group
Group type: COMPARATOR
Intervention: Control (eyes open or closed without light touch contact)
Number of subjects: 10
Study 14984917 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma brain natriuretic peptide (BNP)
Number of subjects: 4300
Study 14984917 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine (NE)
Number of subjects: 4300
Study 14984917 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma renin activity (PRA)
Number of subjects: 4300
Study 14984917 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma aldosterone (aldo)
Number of subjects: 4300
Study 14984917 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma endothelin
Number of subjects: 4300
Study 14984917 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (angiotensin receptor blocker)
Number of subjects: 4300
Study 11444676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) 50 mg
Number of subjects: 78
Study 11444676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 78
Study 11444676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 9396556 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified activated protein C resistance functional assay
Number of subjects: 115
Study 8359082 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 40
Study 8359082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3525523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 11
Study 3525523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31977076 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (5 mg)
Number of subjects: 24
Study 31977076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29099950 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 65
Study 29099950 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed surgery)
Number of subjects: 65
Study 26960406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention with home medication management review
Number of subjects: 112
Study 26960406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist intervention)
Number of subjects: 112
Study 24595942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g dehydrated garlic powder
Number of subjects: 60
Study 24595942 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g dehydrated garlic powder
Number of subjects: 60
Study 24595942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22265697 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg per day plus goserelin 3.6 mg/month
Number of subjects: 204
Study 22265697 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg per day plus goserelin 3.6 mg/month
Number of subjects: 204
Study 22265697 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 204
Study 22265697 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 204
Study 19576321 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin use
Number of subjects: 1803
Study 19576321 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) for > or =6 months
Number of subjects: 1803
Study 17615073 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided antibiotic therapy
Number of subjects: 1002
Study 17615073 — intervention group
Group type: COMPARATOR
Intervention: Guidelines-enforced management
Number of subjects: 1002
Study 14989794 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH (150 IU daily)
Number of subjects: 431
Study 14989794 — intervention group
Group type: COMPARATOR
Intervention: r‐hFSH alone
Number of subjects: 431
Study 14989794 — intervention group
Group type: COMPARATOR
Intervention: r‐hFSH alone (<35 years)
Number of subjects: 431
Study 14989794 — intervention group
Group type: COMPARATOR
Intervention: r‐hFSH alone (≥35 years)
Number of subjects: 431
Study 14989794 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH (150 IU daily) (<35 years)
Number of subjects: 431
Study 14989794 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH (150 IU daily) (≥35 years)
Number of subjects: 431
Study 11668407 — intervention group
Group type: COMPARATOR
Intervention: Pure cut current alone
Number of subjects: 142
Study 11668407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination of pure cut then blended current
Number of subjects: 142
Study 9766143 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care projects
Number of subjects: 0
Study 9766143 — intervention group
Group type: COMPARATOR
Intervention: Large scale campaigns
Number of subjects: 0
Study 7905722 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (600 mg/d adjusted for weight)
Number of subjects: 312
Study 7905722 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (600 mg/d)
Number of subjects: 312
Study 2733733 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective isolation with disposable, non-waven, polypropylene gowns and nonsterile latex gloves
Number of subjects: 70
Study 2733733 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 70
Study 6581281 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam titration (mean dose = 25.6 mgs)
Number of subjects: 20
Study 6581281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diazepam (12.5 mg), fentanyl (0.1 mg), and methohexital (mean dose = 18.0 mg)
Number of subjects: 20
Study 6581281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diazepam (15.0 mg) and methohexital (mean dose = 27.0 mg)
Number of subjects: 20
Study 6581281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31905090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (an inhibitor of catechol‐O‐methyltransferase [COMT])
Number of subjects: 0
Study 31905090 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (a DA agonist with preferential affinity for the D2 receptor)
Number of subjects: 0
Study 31905090 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 31905090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30929973 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG without prior PCI
Number of subjects: 1212
Study 30929973 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with prior PCI
Number of subjects: 1212
Study 30929973 — intervention group
Group type: COMPARATOR
Intervention: MED (control group)
Number of subjects: 1212
Study 29067428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (maintained at 33.5°C for 96 hours)
Number of subjects: 168
Study 29067428 — intervention group
Group type: COMPARATOR
Intervention: Noncooled (maintained at 37.0°C)
Number of subjects: 168
Study 29067428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 168
Study 25667241 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential intervention (supervised diet and exercise)
Number of subjects: 33
Study 24928269 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydimethylsiloxane (Macroplastique)
Number of subjects: 275
Study 24928269 — intervention group
Group type: COMPARATOR
Intervention: Dextranomer/hyaluronic acid copolymer (Deflux)
Number of subjects: 275
Study 22039289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg twice daily
Number of subjects: 0
Study 22039289 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine 100 mg twice daily
Number of subjects: 0
Study 22039289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of oseltamivir and rimantadine
Number of subjects: 0
Study 22039289 — intervention group
Group type: COMPARATOR
Intervention: Control (monotherapy)
Number of subjects: 0
Study 20054875 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (e.g., olanzapine, quetiapine, risperidone)
Number of subjects: 0
Study 20054875 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 17433007 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (n=26)
Number of subjects: 50
Study 17433007 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic placebo beverage (n=24)
Number of subjects: 50
Study 16372579 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/HCTZ 12.5 mg
Number of subjects: 0
Study 16372579 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg/HCTZ 12.5 mg
Number of subjects: 0
Study 11890866 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (vaccines involving monoclonal antibodies or immune effector cells)
Number of subjects: 0
Study 11890866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-based therapies using tumour cells as vaccine components
Number of subjects: 0
Study 11890866 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune cells (e.g., T-lymphocytes and dendritic cells)
Number of subjects: 0
Study 9815522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 5 years
Number of subjects: 37000
Study 9815522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen with chemotherapy
Number of subjects: 37000
Study 8121974 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention
Number of subjects: 80
Study 8121974 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy
Number of subjects: 80
Study 8121974 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention plus Expectancy
Number of subjects: 80